Cancer Treatment News and Research

RSS

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

International implementation of breast health guidelines for developing countries published by Cancer

A special supplement of the Oct. 15 journal Cancer for the first time details guidelines for low- and middle-income countries to implement breast cancer programs to detect and treat the most common disease among women worldwide.

6 Oct 2008

Cancer treatment by linear accelerator is a reality now in India

The first patient was successfully treated by the state-of-the-art technology in radiotherapy - linear accelerator, which began functioning last week at RR Cancer Institute and Research Centre, Sri Ram Murti Smarak Institute of Medical Sciences (SRMSIMS), Bareilly in India.

5 Oct 2008

Experts confront cancer trend: aging population, new challenges

A growing cadre of specialists - geriatric oncologists - is the latest group of medical pioneers to meet the challenge of a rising cancer incidence among older adults. They are investigating how to fill the gaps in the way oncology is practiced today, which sometimes neglects the special needs of the elderly.

2 Oct 2008

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

A new study by scientists in the United States has revealed that vitamin C may blunt the effectiveness of chemotherapy treatment.

1 Oct 2008

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.

30 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Research evaluates acupressure for chemo induced nausea

New research commissioned by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme is evaluating acupressure wristbands for the management of chemotherapy-induced acute and delayed nausea.

23 Sep 2008

U.S. authorities gunning for makers of bogus cancer cures

Government authorities in the United States are gunning for companies peddling bogus cancer cures.

22 Sep 2008

Advisers to Presidential candidates discuss positions on reimportation, generics, biotechnology medications

Democratic presidential nominee Sen. Barack Obama (Ill.) and Republican presidential nominee Sen. John McCain (Ariz.) have begun "reviewing their support" for prescription drug reimportation in response to recent cases of contaminated medications and other products from other nations, advisers to the candidates said on Thursday during the annual conference of the Generic Pharmaceutical Association in Washington, D.C., Reuters/Boston Globe reports.

22 Sep 2008

Discovery of promising new chemotherapy target for a deadly form of leukemia

Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.

17 Sep 2008

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

15 Sep 2008

Surveillance mammography after treatment for primary breast cancer

The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer.

14 Sep 2008

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.

7 Sep 2008

Height linked to risk of prostate cancer

A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say Bristol researchers who conducted their own study on the connection and also reviewed 58 published studies.

3 Sep 2008

A man's height linked to prostate cancer development and progression

A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.

3 Sep 2008

Many people mistaken about the causes of cancer

A large international survey for the International Union Against Cancer (UICC) has revealed that many people have misconceptions about what causes cancer.

27 Aug 2008

Global survey highlights need for cancer prevention campaigns to correct misbeliefs

Many people hold mistaken beliefs about what causes cancer, tending to inflate the threat from environmental factors that have relatively little impact while minimizing the hazards of behaviours well established as cancer risk factors, according to the first global survey on the topic.

26 Aug 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

ICMT enzyme shows potential as target in treating blood cancer

A discovery by a research team with the Sahlgrenska Academy at Gothenburg University in Sweden may lead to new treatments for blood cancer and other diseases. By stopping the production of a specific enzyme, ICMT, researchers were able to alleviate disease symptoms in mice with blood cancer.

21 Aug 2008